Monte Rosa Therapeutics Announces Interim MRT-8102 Phase 1 Study Results Presentation
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology firm focused on developing innovative molecular glue degrader (MGD)-based therapies, will present interim results from its ongoing Phase 1 study of MRT-8102 on January 7, 2026, at 8:00 a.m. ET. The live webcast will provide insights into the efficacy of MRT-8102, particularly in its Part 3 CRP proof-of-concept cohort targeting patients with heightened cardiovascular disease risk.
Details of the Upcoming Presentation
The conference call and webcast will detail preliminary clinical findings from the NEK7-directed MGD MRT-8102 study. Interested participants can access the webcast through the “Events & Presentations” section on Monte Rosa’s official website at ir.monterosatx.com.
Registration for the conference call is available via a designated link, and an archived version of the webcast will be accessible for 30 days post-event.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics specializes in the development of highly selective molecular glue degraders aimed at treating patients with serious medical conditions. Notably, MGDs are a groundbreaking class of small molecule protein degraders that present novel treatment options for diseases resistant to other therapeutic modalities.
- Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine utilizes:
- AI-guided chemistry
- Diverse chemical libraries
- Structural biology
- Proteomics
- Monte Rosa boasts a leading pipeline of first-in-class and only-in-class MGDs targeting:
- Autoimmune diseases
- Inflammatory diseases
- Oncology
Currently, the company has three clinical programs in progress and collaborates with prominent pharmaceutical firms in fields like immunology, oncology, and neurology.
Contact Information
For investor inquiries, please contact Andrew Funderburk at afunderburk@monterosatx.com. Media representatives can reach out to Cory Tromblee at media@monterosatx.com.